1. Home
  2. ICCC vs CELU Comparison

ICCC vs CELU Comparison

Compare ICCC & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCC
  • CELU
  • Stock Information
  • Founded
  • ICCC 1982
  • CELU 2016
  • Country
  • ICCC United States
  • CELU United States
  • Employees
  • ICCC N/A
  • CELU N/A
  • Industry
  • ICCC Biotechnology: Pharmaceutical Preparations
  • CELU Biotechnology: Pharmaceutical Preparations
  • Sector
  • ICCC Health Care
  • CELU Health Care
  • Exchange
  • ICCC Nasdaq
  • CELU Nasdaq
  • Market Cap
  • ICCC 55.5M
  • CELU 56.9M
  • IPO Year
  • ICCC 1987
  • CELU N/A
  • Fundamental
  • Price
  • ICCC $6.19
  • CELU $1.76
  • Analyst Decision
  • ICCC
  • CELU Strong Buy
  • Analyst Count
  • ICCC 0
  • CELU 1
  • Target Price
  • ICCC N/A
  • CELU $6.00
  • AVG Volume (30 Days)
  • ICCC 18.9K
  • CELU 145.6K
  • Earning Date
  • ICCC 11-13-2025
  • CELU 12-05-2025
  • Dividend Yield
  • ICCC N/A
  • CELU N/A
  • EPS Growth
  • ICCC N/A
  • CELU N/A
  • EPS
  • ICCC 0.20
  • CELU N/A
  • Revenue
  • ICCC $28,274,756.00
  • CELU $44,590,000.00
  • Revenue This Year
  • ICCC N/A
  • CELU N/A
  • Revenue Next Year
  • ICCC N/A
  • CELU $76.00
  • P/E Ratio
  • ICCC $31.45
  • CELU N/A
  • Revenue Growth
  • ICCC 21.75
  • CELU 4.45
  • 52 Week Low
  • ICCC $3.38
  • CELU $1.00
  • 52 Week High
  • ICCC $7.60
  • CELU $5.22
  • Technical
  • Relative Strength Index (RSI)
  • ICCC 50.47
  • CELU 41.14
  • Support Level
  • ICCC $6.07
  • CELU $1.62
  • Resistance Level
  • ICCC $6.31
  • CELU $1.88
  • Average True Range (ATR)
  • ICCC 0.28
  • CELU 0.12
  • MACD
  • ICCC 0.01
  • CELU -0.01
  • Stochastic Oscillator
  • ICCC 44.19
  • CELU 33.31

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: